Immunofluorescence for CXCR4, MET, and CD44 confirmed that CXCR4+MET+CD44+ cells are rare in ccRCC tumors and subcutaneous PDX (Fig. 2d). This evidence concerns the gene CXCR4 and nonpapillary renal cell carcinoma.